Compare Apollo Global Management Ord Shs (APO) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Davita Inc — how do they compare? Apollo Global Management Ord Shs trades at $140.47 (market cap $82.84B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Apollo Global Management Ord Shs is far larger — about 7.3× Davita Inc's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| APO | DVA | |
|---|---|---|
Market Cap | $82.84B | $11.38B |
Sector | Financials | Health |
52-Week High | $152.70 | $240.96 |
52-Week Low | $100.30 | $103.87 |
Enterprise Value | -$168.65B | $24.10B |
Dividend Yield | 1.6% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
